

# Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead

Kedar Kirtane <sup>1</sup>, Hany Elmariah,<sup>2</sup> Christine H Chung,<sup>1</sup> Daniel Abate-Daga<sup>3</sup>

**To cite:** Kirtane K, Elmariah H, Chung CH, *et al.* Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. *Journal for ImmunoTherapy of Cancer* 2021;**9**:e002723. doi:10.1136/jitc-2021-002723

Accepted 21 June 2021

## ABSTRACT

While immune checkpoint inhibitors (ICIs) have ushered in major changes in standards of care for many solid tumor malignancies, primary and acquired resistance is common. Insufficient antitumor T cells, inadequate function of these cells, and impaired formation of memory T cells all contribute to resistance mechanisms to ICI. Adoptive cellular therapy (ACT) is a form of immunotherapy that is rapidly growing in clinical investigation and has the potential to overcome these limitations by its ability to augment the number, specificity, and reactivity of T cells against tumor tissue. ACT has revolutionized the treatment of hematologic malignancies, though the use of ACT in solid tumor malignancies is still in its early stages. There are currently three major modalities of ACT: tumor-infiltrating lymphocytes (TILs), genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T cells. TIL therapy involves expansion of a heterogeneous population of endogenous T cells found in a harvested tumor, while TCRs and CAR T cells involve expansion of a genetically engineered T-cell directed toward specific antigen targets. In this review, we explore the potential of ACT as a treatment modality against solid tumors, discuss their advantages and limitations against solid tumor malignancies, discuss the promising therapies under active investigation, and examine future directions for this rapidly growing field.

function of these cells, and impaired formation of memory T cells.<sup>6</sup>

Adoptive cellular therapy (ACT) is another form of immunotherapy that is a rapidly growing area of clinical investigation which involves removing a patient's or donor's T cells, growing and/or modifying them in a laboratory, and reinfusing them back to the patient. In contrast to ICIs which block T-cell inhibitory receptors, ACT depends on ex vivo expansion of T cells which may allow certain inhibitory immune regulators to be bypassed. Furthermore, some forms of ACT entail genetic modification or re-engineering of T cells which can help to increase T-cell specificity. Most forms of ACT are combined with lymphodepletion chemotherapy which helps improve T-cell proliferation and persistence.<sup>7</sup> The different forms of ACT therefore have the strong potential to address many of the limitations of ICI by its ability to augment the number, specificity, and reactivity of T cells against tumor tissue.

There are currently three major modalities of ACT: tumor-infiltrating lymphocytes (TILs), genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T cells. TIL therapy involves expansion of a heterogeneous population of endogenous T cells found in a harvested tumor, while CAR T cells and TCRs involve expansion of a genetically engineered T-cell directed toward specific antigen targets. While successful application of ACT has been seen in hematologic malignancies,<sup>8–10</sup> ACT in solid tumors is still in its early stages. In this review, we explore the potential of ACT as a treatment modality against solid tumors, discuss their advantages and limitations against solid tumor malignancies, discuss the promising therapies under active investigation, and examine future directions for this rapidly growing field.

## INTRODUCTION

Immune checkpoints refer to a collection of pathways that normally serve to prevent the immune system from destroying healthy cells. Cancer cells take advantage of these innate mechanisms and subsequently evade T-cell responses which would otherwise result in tumor destruction.<sup>1</sup> It is now well known that blockade of these immune checkpoints can result in significant tumor regression.<sup>2</sup> Consequently, the immune checkpoint inhibitor (ICI) revolution has ushered in major changes in standards of care for a variety of solid tumor malignancies including melanoma,<sup>3</sup> lung cancer,<sup>3 4</sup> and head and neck cancer.<sup>5</sup> Despite the robust successes of ICI, primary and acquired resistance is common and is attributable to several factors, including insufficient antitumor T cells, inadequate



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida, USA

<sup>2</sup>Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA

<sup>3</sup>Departments of Immunology, Cutaneous Oncology, and Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA

### Correspondence to

Dr Kedar Kirtane;  
kedar.kirtane@moffitt.org

## TYPES OF ACTS

### Tumor-infiltrating lymphocytes

TILs refer to lymphocytes that have left the bloodstream and entered the tumor. TILs are a heterogeneous population of cells that are polyclonal and have broad antigen recognition in tumor cells.<sup>11</sup> It is believed CD8<sup>+</sup> and CD4<sup>+</sup> T-cell populations play a critical role in tumor control through a variety of mechanisms.<sup>12–13</sup> Activated CD8<sup>+</sup> T cells are able to produce proinflammatory cytokines and cause tumor cell destruction, while CD4<sup>+</sup> T cells can promote the production of antibody-producing plasma cells and also help to activate CD8<sup>+</sup> T-cell responses. The favorable prognostic significance of a rich T-cell infiltrate has long been reported in melanoma,<sup>14</sup> as well as other tumors including head and neck squamous cell carcinoma (HNSCC),<sup>15</sup> cervical cancer,<sup>15–16</sup> and lung cancer.<sup>17</sup> Unfortunately, these existing TILs are rendered ineffective due to tumor microenvironments filled with inflammatory infiltrates that are enriched with suppressive regulatory T cells and myeloid suppressor cells.<sup>18</sup>

As a therapeutic strategy, using adoptive cellular transfer of TILs allows for an expansion of immune cells away from this suppressive tumor microenvironment. This process involves harvesting and isolation of TILs from a resected tumor, expansion *in vitro*, and then reinfusion back into the patient. While several animal studies had demonstrated the potential of isolated immune cells to mediate tumor regression,<sup>19–20</sup> the first in-human study of TILs was performed in 1988 in patients with metastatic melanoma.<sup>15</sup> Researchers isolated extracted lymphocytes from resected melanoma specimens, expanded them *in vitro*, and then reinfused them back to the patients after a dose of cyclophosphamide chemotherapy. Patients in this study were also given adjuvant interleukin-2 (IL-2), a strategy based on the observation of potentiated tumor responses from immune cells with this cytokine in murine models.<sup>21–22</sup> This study found that adoptive cellular transfer of TILs resulted in a 55% objective response rate (ORR). This landmark study was able to prove that not only was TIL therapy safe but also it could be effective in eradicating tumor cells.

Since then, many studies have been done with TILs in melanoma. More recent data presented in 2020 at the American Society of Clinical Oncology annual meeting assessed melanoma patients whose cancers had progressed after either PD-1 blockade or a BRAF±MEK inhibitor for BRAF V600-positive disease. Of the 66 patients treated, there was an ORR of 36.4% and at a median follow-up of 8.8 months, the median duration of response was not reached.<sup>23</sup> Furthermore, the disease control rate was 80%. The therapy was well tolerated with a majority of the toxicities being related to lymphodepleting chemotherapy and/or IL-2. A majority of the patients who responded to the TILs had progressed on ICI, suggesting that the mechanisms between the two are not redundant. This is especially important to consider given that the early TILs studies were done prior to the checkpoint inhibitor era. How to adequately generate and when to

sequence TILs with checkpoint inhibitors will need to be elucidated with future studies. There are already data to suggest that patients whose cancers have progressed on ICI still have a significant amount of tumor-reactive T cells.<sup>24</sup> Novel strategies to reinvigorate these T cells in this patient population remains difficult but may help to further delineate the role of TILs in the ICI era.

Some of the differences seen between the most recent studies on TIL therapy in melanoma and the studies done in the 1980s are due to a better understanding of the importance of lymphodepletion. Lymphodepletion is believed to contribute to enhanced antitumor efficacy of TILs not only by the removal of regulatory T cells which hinder CD8<sup>+</sup> T-cell immunity<sup>25</sup> but also by removing homeostatic cytokine sinks that otherwise would weaken effector cell proliferation.<sup>26</sup> While the initial studies in the 1980s used a single dose of cyclophosphamide for lymphodepletion, the more recent studies used more intensive regimens either through the addition of fludarabine or total body irradiation. Although not definitive, some data suggest that ORRs are higher for TIL populations that have more intensive lymphodepletion regimens.<sup>7</sup>

TIL therapy has been most extensively studied in melanoma, though there are emerging data to suggest a potential therapeutic role of TILs in a variety of other solid tumors as well.<sup>27</sup> The more recent observations that these other tumor types are also responsive to ICI provided the proof of principle that endogenous T cells are capable of mediating tumor regression in these solid cancers. For these tumor types, TILs could potentially have several advantages to ICI. ICI by its very nature relies on tumor-reactive T cells since its primary mechanism of action is to remove the breaks on the immune system. However, since it is speculated that many of these T cells may be dysfunctional<sup>28</sup> (or absent due to low tumor immunogenicity in some cancers),<sup>29</sup> this strategy does not work for a relevant proportion of patients. The generation of TILs relies on the creation of a population of T cells that may be able to overcome this dysfunction either through coculture with IL-2 and/or selection for tumor antigen specific T cells.

There are now several multi-institutional trials exploring TIL therapy for HNSCC, lung cancer, and cervical cancer (table 1). While previously HNSCC were thought to lack immune infiltration, a recent analysis of The Cancer Genome Atlas found that transcriptomes from HNSCC were some of the most highly immune infiltrated.<sup>30</sup> Furthermore, CD8<sup>+</sup> T-cell infiltrates in HNSCC are associated with improved survival and favorable clinical outcomes.<sup>31</sup> These studies suggest that the therapeutic approach using TILs could be very promising.

While some of these trials have shown significant successes in TILs as a treatment modality, widespread adoption has not yet been seen. The traditional manufacturing process takes approximately 5–7 weeks from tumor resection to TIL production<sup>32</sup> which may be too long for some patients with metastatic disease. Furthermore, many times isolated TILs are unable to grow or demonstrate strong effector responses,<sup>33</sup> which may reflect tumor tissue

**Table 1** Selected adopted cellular therapy trials in solid tumor malignancies

Type of therapy	Target	Phase	Clinical trial number
CAR T	EGFR	I	NCT03618381
CAR T	B7H3; CD19	I	NCT04483778
CAR T	HER2	I	NCT03740256
CAR T	HER2	I	NCT04660929
CAR T	Glypican 3	I	NCT02932956
CAR T	PSCA	I/II	NCT02744287
CAR T	ROR1	I	NCT02706392
CAR T	Mesothelin	I	NCT03054298
CAR T	TnMUC1	I	NCT04025216
TIL	Melanoma; HNSCC	I	NCT03991741
TIL	Melanoma; HNSCC; NSCLC	II	NCT03645928
TIL	Ovarian cancer; pancreatic ductal adenocarcinoma; colorectal cancer	II	NCT03610490
TIL	Ovarian cancer; anaplastic thyroid cancer; osteosarcoma	II	NCT03449108
TIL	Sarcoma	I	NCT04052334
TIL	Cervical cancer	II	NCT03108495
TIL	Various solid tumor cancers	II	NCT03935893
TCR	MAGE A4/8	I	NCT03247309
TCR	Various solid tumor cancers—neoantigen TCRs	I	NCT03970382
TCR	Preferentially expressed antigen in melanoma-positive tumors	I	NCT03686124
TCR	MAGE A3/A6	I	NCT03139370
TCR	HPV16+ cancers	I	NCT03912831
TCR	MAGE A4+ HNSCC	I	NCT04408898
TCR	NY-ESO-1	I/II	NCT02650986

CAR, chimeric antigen receptor; EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PSCA, prostate stem cell antigen; TCR, T-cell receptor; TIL, tumor-infiltrating lymphocyte.

with poor immune infiltration that existing processes are unable to overcome. Combination approaches such as the addition of checkpoint blockade to TIL products (NCT02621021; NCT03645928; NCT03215810) aim to improve TIL efficacy and to help overcome some of these issues. For example, recently preliminary data from a TIL therapy in lung cancer with ICI were presented at the American Association of Cancer Research (AACR) meeting in 2020. In this study, patients with metastatic non-small cell lung cancer (NSCLC) whose cancers had progressed on nivolumab were given TILs and then resumed nivolumab after TIL infusion. Of the 20 enrolled patients, most of the patients had initial tumor regression with a median best overall change in their tumor of approximately 38%.<sup>34</sup> Two patients in the study had complete regression of their tumor which was ongoing for nearly a year. Further studies will help to elucidate the potential benefits of this combination therapy in lung as well as other tumors.

### Genetically engineered TCR

TCR-engineered T-cell technologies are a natural extension of the rationale for TIL therapy. Since TILs are

ostensibly equipped with acquired tumor recognition, this raised the possibility of genetically modifying naive lymphocytes to also recognize tumor antigen. In the 1980s, Dembic *et al* identified that TCR  $\alpha$  and  $\beta$  chains are the critical components that determine antigen specificity of T cells.<sup>35</sup> These TCR  $\alpha$  and  $\beta$  heterodimers form TCR-CD3 signaling complexes with specificities for target antigens presented to it by human leukocyte antigen (HLA)-dependent mechanisms.<sup>36</sup> Kessels *et al* used retroviral vectors to transduce specific TCRs into T cells via gene transfer into murine models.<sup>37</sup> In the late 1990s at the National Institutes of Health (NIH), researchers were able to successfully transduce human peripheral blood lymphocytes with genes encoding a MART-1-specific TCR, found in a majority of melanoma tumors.<sup>38</sup> With this established framework in mind, Morgan *et al* tested an anti-MART-1 TCR on 15 patients with melanoma.<sup>39</sup> The study demonstrated clinical responses in 2 of 15 patients with metastatic melanoma providing proof of principle of TCRs as a feasible strategy to affect tumor regression.

A number of trials with different antigen targets have shown clinical activity of TCRs across solid tumor types.

For example, the NY-ESO-1 cancer/testis antigen is found in approximately 25% of melanomas, and one study of antigen-positive tumors found that a TCR directed toward this target resulted in 5 of 11 patients having an objective clinical response with 2 of those patients demonstrating complete regression of their disease.<sup>40</sup> NY-ESO-1 is also expressed in approximately 18% of NSCLCs<sup>41 42</sup> and 80% of synovial sarcomas.<sup>43 44</sup> A TCR for NY-ESO-1 in solid tumors (NCT02650986) is ongoing and will hopefully clarify the effectiveness of this TCR for these patient populations. Another therapy being actively studied is a MAGE-A3/A6 TCR (NCT03139370). Similar to NY-ESO-1, MAGE is a cancer-germline antigen that is expressed in multiple cancer types.<sup>45</sup> Proof of concept of this as a possible therapy was explored in a study of nine patients with cancer treated with an anti-MAGE-A3 TCR in 2013,<sup>46</sup> though several of the patients experienced a life-threatening neurologic toxicity due to cross-reactivity with the MAGE-A12 protein expressed on a subset of neurons. Optimization of these TCRs to avoid activation in areas of the body without tumor is needed to avoid potentially life-threatening side effects.

Identification of TCR targets for virally mediated cancers such as HPV or Epstein-Barr virus may also be an especially promising strategy. Viral antigens which are presented in HLA-dependent mechanisms are constitutively expressed by tumor cells and expression of these antigens is unlikely to be found on normal tissue. In one study at the NIH of an HPV E7 TCR in HLA-A2\*01-positive patients, 6 of 12 patients demonstrated objective clinical responses with no cytokine release syndrome (CRS).<sup>47 48</sup> Of the patients who did not have clinical responses, defects were found in HLA-A2\*01 or  $\beta$ -2 microglobulin, both of which are considered necessary for peptide antigen recognition of this specific TCR. Ongoing trials are testing TCRs in HPV-related cancers (NCT03912831).

However, virally mediated malignancies represent a small proportion of the cancer epidemiologic burden. Attempts to broaden the TCR strategy may largely depend on the identification and targeting of neoantigens, epitopes that arise from somatic mutation and are not present on normal cells. Neoantigens are generally a result of non-synonymous somatic mutations. Tumor neoantigens are presented by major histocompatibility complex (MHC), have the potential for garnering an adaptive immune response, and represent ideal targets for ACT since by definition they are not present on normal cells.<sup>49</sup> Some data even suggest that objective responses to ICI are mediated by neoantigen-specific T cells.<sup>50–52</sup> Identification of neoantigen T cells would allow for the creation of TCR cell therapy products that are highly individualized and specific. Next-generation sequencing, mass spectrometry, whole-exome/transcriptome sequencing, and high-throughput T-cell-based assays are all approaches being used to identify neoantigen T cells currently.<sup>53</sup> One study using neoantigen TCRs in combination with ICI in patients with incurable solid tumor malignancies is ongoing (NCT03970382). The key to the neoantigen

strategy will heavily rely on the ability to identify and development high-affinity and immunogenic TCRs. Enhancing genetically re-engineered TCR on-target cytotoxicity and outcomes will depend on a variety of factors including, but not limited to, improving the affinity of the peptide MHC–TCR interaction and reducing competition from native TCRs which would otherwise reduce transgenic TCR concentrations.<sup>54</sup>


Nevertheless, identifying individual patient neoantigens is laborious and costly, so targeting a shared mutational antigen that is specific to tumors and clonally conserved may prove more practical. Targeting neoantigens derived from potential driver oncogenes such as BRAF V600E or PIK3CA<sup>55</sup> may prove to be a more fruitful strategy since these neoantigens may be more likely to appear in a significant portion of patients within the same tumor type.

These strategies no matter how successful may prove ultimately are ineffectual if the re-engineered TCRs are unable to meaningfully traffic to tumor sites. To overcome this barrier, multiple tumor types may benefit from intratumoral or locoregional administration of TCRs. For example, in light of the accessibility of most local lesions for HNSCC, there are clinical trials studying intratumoral delivery of an E7 oncoprotein TCR for borderline resectable and unresectable HPV-associated oropharyngeal cancers (NCT04044950). An added benefit of this will be the hopeful avoidance of systemic toxicities associated with some TCR therapies. Other tumor types with accessible lesions, such as cutaneous malignancies, or those confined to a cavity, such as peritoneal or intracranial diseases, may benefit from this strategy.

It is worthy of note that genetically engineered TCRs are HLA restricted and thus must be HLA matched to be effective. Many of the TCRs in ongoing investigation are restricted to HLA-A\*0201, which is under-represented in African and Asian populations while present in nearly half of Caucasian populations.<sup>56</sup> As TCR studies become more prolific, it is imperative that non-HLA-A\*02 serotypes are considered so that these novel technologies can benefit diverse patient populations. Furthermore, since HLA alterations may function as escape mechanisms for some TCRs, the ability to overcome these resistance mechanisms will be critical to future successes.

### CAR T cell

Similarly to TCRs, CAR T cells are lymphocytes that are genetically modified to have specificity for tumor antigens. In contrast to TCRs, CAR T cells recognize extracellular antigens independent of HLA presentation (figure 1).<sup>51</sup> CAR T cells consist of a T-cell activating domain which allows for cell proliferation and a single-chain variable fragment which confers specificity for a target. While initial generations of CARs were not able to sustain T-cell responses, subsequent generations of CAR T cells include one or more costimulatory domains (usually CD28 or 4-1BB) to enhance its proliferative capacity.<sup>57–59</sup>



**Figure 1** Differences between chimeric antigen receptor (CAR) T cells and re-engineered T-cell receptors (TCRs). CAR T cells recognize antigens expressed on the cell surface via an antigen-recognition domain (signal-chain variable fragment). This domain is connected to a spacer, transmembrane domain, and a single or multiple costimulatory domains which then trigger downstream T-cell activation via a signaling domain. TCRs are heterodimers with an  $\alpha$  and  $\beta$  subunit which recognizes intracellular peptide antigens presented to it by the major histocompatibility complex (MHC). The heterodimer is connected to a CD3 signal transduction complex which acts to activate downstream T-cell activation. Created with <http://www.biorender.com/>.

The first successful CAR T cells were developed to have specificity for CD19 and were eventually FDA approved for acute lymphoblastic leukemia and refractory large

B-cell lymphomas.<sup>9 60</sup> Currently, different CAR T-cell targets in solid tumor malignancies are in active investigation.



One study used an intracranial CAR T cell directed against IL-13 receptor  $\alpha$  2 (IL13R $\alpha$ 2) in a patient with multifocal glioblastoma multiforme (GBM) and found complete regression of tumor lasting nearly 8 months.<sup>61</sup> Another phase I trial is studying the safety and preliminary efficacy of a CAR T-cell directed against ROR1, a transmembrane tyrosine kinase receptor, found in breast and lung cancers (NCT02706392). Presentation of preliminary data from this study at the AACR demonstrated that four of five patients with breast and lung cancer had a mixed response with decreased disease burden at some of their metastatic sites.<sup>62</sup> Another study used a regionally delivered mesothelin-targeted CAR T cell with checkpoint inhibition in patients with malignant pleural mesothelioma and metastatic lung and breast cancer.<sup>63</sup> The mesothelin-specific CAR T cell was administered intrapleurally and then followed by ICI. Of the 14 evaluable patients treated with ICI after CAR T administration, 2 had a complete response, 5 had a partial response, and 4 had stable disease. No CAR T-cell therapy-related toxicities greater than grade 1 were observed in the study. The study is currently ongoing (NCT02414269).

A few other novel CAR T targets have shown preliminary efficacy. One phase I, open-label dose-escalation study of a HER2 CAR T cell for patients with glioblastoma found no dose-limiting toxicities and a median overall survival of 11.1 months from cell infusion. Of the 16 evaluable patients, 1 had a partial response lasting nearly 9 months, while 7 had stable disease ranging from 8 weeks to 29 months.<sup>64</sup> Another study used a CAR T directed toward prostate-specific membrane antigen (PSMA) in patients with castrate-resistance prostate cancer.<sup>65</sup> The PSMA-CAR was coupled to a dominant negative receptor for TGF $\beta$  in order to inhibit the immunosuppressive activity of TGF $\beta$  in the tumor microenvironment. At 12 weeks, 4 of 10 treated patients had at least 30% reduction of their prostate-specific antigen levels. A majority of the patients developed grade 2 or higher CRS, a constellation of inflammatory and clinical findings occurring commonly in patients with lymphoma receiving CAR T therapy. The CRS was associated with increases in IL-6, IL-15, IL-2, and IFN $\gamma$ . Parallel to the PSMA CAR T, there is another promising target directed toward prostate stem cell antigen (PSCA) with its trial ongoing (NCT03873805).<sup>66</sup> PSCA is also expressed in some gastric and pancreatic cancers and has shown preliminary safety and efficacy in this population.<sup>67</sup> Lastly Claudin18.2, a stomach-specific isoform of Claudin-18, is overexpressed in some gastric and pancreatic adenocarcinomas. This is a new and evolving treatment option for these malignancies. One study found that a Claudin18.2 CAR T in gastric and pancreatic adenocarcinoma patients resulted in an ORR of 33%, a median PFS of 130 days, and no serious adverse events.<sup>68</sup>

Nevertheless, the development of CAR T cells for solid tumors has been difficult. While its lack of dependence on HLA-specific recognition is an advantage with regard to general applicability over TCRs, it also limits its effectiveness since it would theoretically only be effective

for a unique, extracellular target which may not exist for many solid tumor malignancies. Furthermore, the limited antigen sensitivity for current CAR T cells allows for relatively easy downregulation of target antigens by tumor cells as a mechanism of acquired resistance. For example, in the seminal trial of tisagenlecleucel, a CD19 CAR T cell for patients with B-cell acute lymphoblastic leukemia,<sup>60</sup> 94% of the assessed patients who relapsed had CD19 antigen loss either through genetic mutation or maximization of CD19 variants with isoforms lacking the transmembrane domain or targeted exon.<sup>69</sup> This proves even more problematic for solid tumor malignancies given the tremendous tumor-associated antigen heterogeneity.<sup>70</sup> One strategy to overcome this is through 'T cells redirected for antigen-unrestricted cytokine-initiated killing' (TRUCKs). These fourth generation CAR T-cell products combine a CAR T cell directed toward a specific antigen with an inducible release of a transgenic protein (usually a cytokine) on activation.<sup>71</sup> Recognition of the tumor antigen by the TRUCK leads to TCR-CD3- $\zeta$ -mediated downstream signaling which leads to eventual release of the protein. This allows for engagement with the tumor cell based on its cognate antigen with a subsequent cytokine-mediated destruction of regulatory T cells or antigen-loss tumor cells that may otherwise facilitate relapse. In one mouse model of an inducible IL-12 CAR T cell directed toward the carcinoembryonic antigen (CEA), transplanted, antigen-heterogenous tumor lesions were eliminated not only as a result of both CAR T-cell engagement with antigen-positive tumor cells but also due to IFN $\gamma$  production by NK and T cells along with activation of macrophages and secreted TNF- $\alpha$ .<sup>71 72</sup> Future CAR T strategies will likely include combinatorial cytokines, multitarget approaches, and novel combination immunotherapeutic strategies, which may help overcome tumor associated antigen heterogeneity and the inhibitory microenvironment of the solid tumor stroma. [Table 1](#) summarizes relevant TCR and CAR T cells currently in active investigation.

## BARRIERS TO ACT FOR SOLID TUMORS

### Target antigen heterogeneity and antigen escape

One of the barriers to the development of effective cellular therapies in solid tumors, specifically for TCRs and CAR T cells, is target antigen heterogeneity. The successes of ACT trials in hematologic malignancies were largely dependent on three factors. First, there was a clear identifiable antigen (CD19). Second, this antigen was homogeneously expressed in the disease of interest. Third, toxicities associated with T-cell activity on other parts of the body (so-called on-target/off-tumor effects) were manageable (eg, immunoglobulin repletion for B-cell depletion)<sup>8</sup> and expression on tumor was much higher than healthy cells allowing for a therapeutic window. In contrast, solid tumor malignancies tend to have more heterogeneity in their antigen profiles,<sup>70</sup> especially since the formation of these cancers is not always dependent

on clonal expansion of an aberrantly expressed antigen as in lymphomas or leukemias. While many of these antigens may be overexpressed in some tumor tissue, there is not consistent expression due to this intratumoral heterogeneity which generally results from genomic instability. Intratumoral heterogeneity is a concern in diffusely metastatic disease, has been found and studied in multiple cancer types, and may help to explain some forms of resistance mechanisms.<sup>73–75</sup> Acquired resistance patterns which manifest as mixed radiographic responses may be a result of the selective pressures of immunotherapies. One study using an epidermal growth factor receptor variant III (EGFRvIII) CAR T cell in patients with recurring glioblastoma found a significant adaptive response from the tumor to avoid destruction after cell infusion.<sup>76</sup> Analysis of tumor specimens demonstrated decreased antigen expression of EGFRvIII in five of seven infused patients. Furthermore, post-CAR T-cell tumor specimens demonstrated an increased expression of immunosuppressive molecules including indoleamine 2,3-dioxygenase (IDO1), PD-L1, and FoxP3-expressing regulatory T cells. This adaptive compensatory response adds to the difficulties in optimizing cellular therapies for the management of solid tumor malignancies.

One strategy to overcome antigen escape and heterogeneity is through the use of a multiantigen recognition circuit involving complementary antigens.<sup>77–78</sup> One example of this is the syn-Notch receptor, which uses an engineered transmembrane receptor to induce expression of a tumor-specific CAR in response to recognition of an extracellular signal.<sup>78–79</sup> One such study found that CD8<sup>+</sup> T cells engineered with a syn-Notch ligand that recognizes a GBM tumor-specific but heterogeneously expressed antigen EGFRvIII and a tumor non-specific EphA2 or IL13R $\alpha$ 2 CAR T ligand resulted in *in vitro* killing of both EGFRvIII<sup>+</sup> and EGFRvIII<sup>-</sup> cells.<sup>77</sup> This ‘prime and kill’ strategy by Choe *et al.*<sup>77</sup> also hypothesized that priming with a tissue-specific antigen called myelin oligodendrocyte glycoprotein could be used in combination with the EphA2 or IL13R $\alpha$ 2 CAR T ligand. This resulted again in *in vitro* killing of GBM target cells with no effect on the priming cells. These results were confirmed *in vivo* in xenografts and demonstrated that the multiantigen recognition circuit resulted in cytotoxic activity in a spatially confined manner. Other strategies to overcome these barriers include bispecific CAR T cells which may optimize tumor cell engagement better than singly targeted therapies across metastatic sites and result in better tumor regression. While clinical trials with dual targeting CAR T cells are not prolific, a proof of concept with a dual-specific CAR T targeting ErbB2 and MUC1 found that engagement with the target antigen resulted in enhanced T-cell proliferation.<sup>80</sup> Making use of these novel designs and antigen gating may help to overcome some of the barriers associated with solid tumor antigen heterogeneity and escape.

Nevertheless, target identification that is specific to tumor cells and avoids normal human tissue has been a


crucial challenge for the development of cellular therapies in solid tumor malignancies. While strategies such as syn-Notch receptors are promising, a number of studies have demonstrated dose-limiting on-target/off-tumor toxicities with currently used technologies. For example, one clinical trial studied a CEA-specific CAR T cell (CEACAM5) and found that expression of this antigen in the lung epithelium likely correlated with the dose-limiting respiratory toxicities from the target antigen being studied.<sup>81</sup> Another study in metastatic renal cell carcinoma using autologous T cells re-engineered against carbonic anhydrase IX found a similar on-target/off-tumor toxicity when patients infused with cell product had profound liver toxicities likely mediated from expression of target antigen on bile duct epithelial cells.<sup>82</sup> The problem of tumor antigen heterogeneity is compounded when viewed in the context of these off-tumor toxicities as even the slightest cross-reactivity could result in life-threatening toxicity.

### T-cell trafficking and infiltration

For effector T-cell-mediated cell death to occur, a T cell must be able to effectively traffic to a tumor and subsequently overcome any suppressive cytokines that would prevent it from fulfilling its goal. It is well known that many metastatic lesions lack lymphocytes, thus providing evidence that effector T cells are not adequately localizing their targets.<sup>83,84</sup> One study in melanoma found that metastatic sites with greater CD8<sup>+</sup> T-cell infiltration also had a preferential expression of six chemokine subsets: CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10.<sup>85</sup> While these chemokine subsets may not be generalizable to all solid tumor malignancies, it suggests that critical chemokine receptor/ligand matches are necessary to allow for effector T-cell migration.<sup>86</sup> Furthermore, the failure of ACTs to traffic to tumor sites as a result of chemokine/receptor mismatch and inhibitory cytokines helps to explain the lack of efficacy to date of these therapies in solid tumors, especially in light of the fact that higher and persistent CAR T levels in the blood of patients with lymphoma were associated with a higher likelihood of response.<sup>9</sup> CAR T products in particular may have less obstacles for trafficking to hematologic tumor cells in the lymph nodes or bone marrow, since T cells are already normally trafficked to these areas.<sup>87</sup> For solid tumor malignancies, any such T-cell product must efficiently move from the bloodstream to the tumor which generally has an overwhelming set of inhibitory cytokines which will prevent this from happening.

### Immunosuppressive tumor microenvironment

The solid tumor microenvironment has optimized its oppression of active effector T cells through a variety of mechanisms including preventing T-cell infiltration and by facilitating anergy. Furthermore, even if a cell therapy product is able to effectively traffic to a tumor, it must overcome a structurally complex microenvironment and macroenvironment with altered extracellular matrices,



**Figure 2** Challenges for adoptive cell therapy (ACT) in solid tumors. Tumor heterogeneity, antigen escape, T-cell trafficking, and an immunosuppressive tumor microenvironment represent some of the most challenging obstacles in solid tumor ACT development. Adapted from 'Challenges for CAR T-cell immunotherapy in solid tumors', by BioRender.com (2021). Retrieved from <https://app.biorender.com/biorender-templates>. IL-10, interleukin-10.

abnormal vasculature, variable interstitial fluid pressure, and shifting hypoxic regions.<sup>88</sup> Many tumor-associated myeloid cells produce immunosuppressive cytokines (eg, IL-10 and TGF- $\beta$ ) which serve to prevent T-cell-mediated destruction of tumor.<sup>89</sup> Furthermore, deterioration of T-cell function may be a result of persistent antigen and inflammatory signal exposure.<sup>90</sup> Some investigators claim that existing dysfunctional CD8<sup>+</sup> T-cell infiltrates in solid tumors may be rejuvenated by checkpoint inhibitor therapy. Using single-cell RNA sequencing, one study found that two distinct tumor CD8<sup>+</sup> T cells existed: progenitor exhausted and terminally exhausted.<sup>91</sup> The former was able to control tumor growth, while the latter was not. This has significant developmental and therapeutic implications for ACT given that transferred T cells must be protected from becoming terminally exhausted. Innate resistance to checkpoint inhibition in patients with solid tumors may be a result of a CD8<sup>+</sup> T-cell infiltrate ratio that favors terminal exhaustion over progenitor exhaustion.

Nevertheless, the cytokine interaction is multifactorial, multifaceted, and incredibly complex, and there is therefore an unmet need with regard to overcoming these inhibitory signals. More recently, CRISPR technologies

have been used to identify genes that are critical to effector T-cell function.<sup>92</sup> These technologies have the ability to create T cells resistant to multiple inhibitory pathways. For example, the generation of ablated Fas receptor CAR T cells using CRISPR allowed for a resistance to Fas ligand activation induced cell death both in vivo and in vitro when challenged with tumor cells.<sup>93</sup> Furthermore, genome-wide CRISPR screens can help to identify potent modulators of TCR activation and effector T-cell function. One such study with CAR T and GBM stem cells using CRISPR screening found Ikaros family zinc finger protein 2 and TLE4 as critical factors in effector T-cell function, and subsequently that targeted knockouts of these genes increased CAR T-cell activity.<sup>92</sup> CRISPR screening may prove to serve a critical role for the development of enhanced CAR T cells that can reliably reverse exhaustion and inhibitory mechanisms of the proinflammatory tumor microenvironment. **Figure 2** summarizes the challenges of ACT in solid tumor malignancies.

#### FUTURE DIRECTIONS AND CONCLUSIONS

The future of ACT will rely heavily on combinatorial regimens and novel structural changes to existing cellular



therapy products to augment clinical efficacy and overcome resistance mechanisms. The addition of checkpoint inhibitors or cytokine modulators such as CD40 can help increase T-cell infiltration, enhance proliferation, and overcome antigen escape.<sup>94</sup> Targeting the tumor microenvironment and/or stroma may also improve the effectiveness of ACTs. For example, adding angiogenic therapies (eg, vascular endothelial growth factor inhibitors) to ACTs may increase tumor infiltration by disrupting the tumor vasculature<sup>95</sup> or engineering macrophages with CARs may help to overcome immunosuppressive cytokines and upregulate antigen presentation.<sup>96</sup> The technologies of dual-specific CAR T cells, synNotch receptors, CRISPR-based modulation of the proinflammatory genes, along with inducible cytokine CAR T cells, neoantigen TCRs, and combination regimens with TILs all represent the future of enhanced ACT. Furthermore, the recent technological breakthroughs of mRNA vaccines are certain to make a strong impact on the field of cellular therapy and immunotherapies as a whole. In the USA alone, there are nearly 50 clinical trials studying ACT products for solid tumor malignancies. As we move forward to the next paradigm shift in cancer treatment, a more informed understanding of the tumor microenvironment, target antigens, resistance mechanisms, and strategies to overcome these mechanisms is critical to improving outcomes through innovation.

**Twitter** Kedar Kirtane @kedar\_kirtane

**Acknowledgements** Editorial assistance was provided by the Moffitt Cancer Center's Office of Scientific Writing by Dr Paul Fletcher and Daley Drucker. No compensation was given beyond their regular salaries.

**Contributors** KK: conceptualization, writing of initial manuscript, and editing. HE, CHC, and DA-D: review and editing of manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** KK: Owns stock in Seattle Genetics, Oncternal Therapeutics, and Veru. HE: None. DA-D: Member of the scientific advisory board of Anixa Biosciences. He receives research funding from Intellia Therapeutics and Bluebird Bio and has been listed as inventor or coinventor in patent applications filed by Moffitt Cancer Center. CHC: Honoraria from Sanofi and Exelixis for ad hoc Scientific Advisory Board participation.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iD

Kedar Kirtane <http://orcid.org/0000-0003-1302-9577>

#### REFERENCES

- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12:252–64.
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. *Science* 1996;271:1734–6.

- Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 2013;369:122–33.
- Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of Non–Small-Cell lung cancer. *New England Journal of Medicine* 2015;372:2018–28.
- Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. *The Lancet* 2019;393:156–67.
- Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. *Br J Cancer* 2018;118:9–16.
- Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *Journal of Clinical Oncology* 2008;26:5233–9.
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med Overseas Ed* 2019;380:45–56.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med* 2017;377:2531–44.
- Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. *New England Journal of Medicine* 2020;382:1331–42.
- Wu R, Forget M-A, Chacon J. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. *Cancer J* 2012;18:160–75.
- Piersma SJ, Jordanova ES, van Poelgeest MIE, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. *Cancer Res* 2007;67:354–61.
- Brambilla E, Le Teuff G, Marguet S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. *J Clin Oncol* 2016;34:1223–30.
- Borst J, Ahrends T, Bąbala N, et al. Cd4+ T cell help in cancer immunology and immunotherapy. *Nat Rev Immunol* 2018;18:635–47.
- Plesca I, Tunger A, Müller L, et al. Characteristics of tumor-infiltrating lymphocytes prior to and during immune checkpoint inhibitor therapy. *Front Immunol* 2020;11:364.
- Clemente CG, Mihm MC, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. *Cancer* 1996;77:1303–10.
- Ward MJ, Thirdborough SM, Mellows T, et al. Tumour-Infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. *Br J Cancer* 2014;110:489–500.
- Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. *Oncogene* 2008;27:5904–12.
- Rosenberg S, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. *Science* 1986;233:1318–21.
- Eberlein TJ, Rosenstein M, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. *J Exp Med* 1982;156:385–97.
- Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. *New England Journal of Medicine* 1988;319:1676–80.
- Donohue JH, Rosenstein M, Chang AE. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. *J Immunol* 1984;132:2123–8.
- Sarnaik A, Khushalani NI, Chesney JA, et al. Long-Term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. *Journal of Clinical Oncology* 2020;38:10006.
- Andersen R, Borch TH, Draghi A, et al. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. *Annals of Oncology* 2018;29:1575–81.
- Antony PA, Piccirillo CA, Akpınarlı A, et al. CD8<sup>+</sup> T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4<sup>+</sup> T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells. *The Journal of Immunology* 2005;174:2591–601.
- Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8<sup>+</sup> T cells. *J Exp Med* 2005;202:907–12.
- Radvanyi LG. Tumor-Infiltrating lymphocyte therapy: addressing prevailing questions. *Cancer J* 2015;21:450–64.

- 28 Jiang P, Gu S, Pan D, *et al.* Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. *Nat Med* 2018;24:1550–8.
- 29 van der Woude LL, Gorris MAJ, Halilovic A, *et al.* Migrating into the tumor: a roadmap for T cells. *Trends in Cancer* 2017;3:797–808.
- 30 Mandal R, Şenbabaoğlu Y, Desrichard A, *et al.* The head and neck cancer immune landscape and its immunotherapeutic implications. *JCI Insight* 2016;1:e89829.
- 31 Kong CS, Narasimhan B, Cao H, *et al.* The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. *Int J Radiat Oncol Biol Phys* 2009;74:553–61.
- 32 Hopewell EL, Cox C, Pilon-Thomas S, *et al.* Tumor-Infiltrating lymphocytes: streamlining a complex manufacturing process. *Cytotherapy* 2019;21:307–14.
- 33 Goff SL, Smith FO, Klapper JA, *et al.* Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. *J Immunother* 2010;33:840–7.
- 34 Creelan B, Wang C, Teer J. Abstract CT056: durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): a phase I trial. *Proceedings: AACR Annual Meeting 2020* 2020.
- 35 Dembić Z, Haas W, Weiss S, *et al.* Transfer of specificity by murine  $\alpha$  and  $\beta$  T-cell receptor genes. *Nature* 1986;320:232–8.
- 36 Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. *Nature* 2017;545:423–31.
- 37 Kessels HW, Wolkers MC, van den Boom MD, *et al.* Immunotherapy through TCR gene transfer. *Nat Immunol* 2001;2:957–61.
- 38 Clay TM, Custer MC, Sachs J. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. *J Immunol* 1999;163:507–13.
- 39 Morgan RA, Dudley ME, Wunderlich JR, *et al.* Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* 2006;314:126–9.
- 40 Robbins PF, Morgan RA, Feldman SA, *et al.* Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *JCO* 2011;29:917–24.
- 41 Balakrishnan A, Goodpaster T, Randolph-Habecker J, *et al.* Analysis of Ror1 protein expression in human cancer and normal tissues. *Clin Cancer Res* 2017;23:3061–71.
- 42 Kim SH, Lee S, Lee CH, *et al.* Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. *Lung* 2009;187:401–11.
- 43 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA A Cancer J Clin* 2020;70:7–30.
- 44 Jungbluth AA, Antonescu CR, Busam KJ, *et al.* Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. *Int J Cancer* 2001;94:252–6.
- 45 Sang M, Lian Y, Zhou X, *et al.* MAGE-A family: attractive targets for cancer immunotherapy. *Vaccine* 2011;29:8496–500.
- 46 Morgan RA, Chinnasamy N, Abate-Daga D, *et al.* Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. *J Immunother* 2013;36:133–51.
- 47 Norberg SM, Nagarsheth N, Doran S, *et al.* Regression of epithelial cancers following T cell receptor gene therapy targeting human papillomavirus-16 E7. *Blood* 2018;132:492.
- 48 Norberg S, Nagarsheth N, Sinkoe A, *et al.* Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers. *Journal of Clinical Oncology* 2020;38:101.
- 49 Chen R, Fulton KM, Twine SM, *et al.* Identification of MHC peptides using mass spectrometry for neoantigen discovery and cancer vaccine development. *Mass Spectrom Rev* 2021;40:110–25.
- 50 Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. *Clinical Cancer Research* 2016;22:807–12.
- 51 Snyder A, Makarov V, Merghoub T, *et al.* Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med Overseas Ed* 2014;371:2189–99.
- 52 Rizvi NA, Hellmann MD, Snyder A, *et al.* Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015;348:124–8.
- 53 Lu Y-C, Robbins PF. Cancer immunotherapy targeting neoantigens. *Semin Immunol* 2016;28:22–7.
- 54 Campillo-Davo D, Flumens D, Lion E. The quest for the best: how TCR affinity, avidity, and functional avidity affect TCR-Engineered T-cell antitumor responses. *Cells* 2020;9:1720.
- 55 Chandran S, Ma J, Klatt MG. T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers. *Molecular Cancer Therapeutics* 2019;18:615.
- 56 Ellis JM, Henson V, Slack R, *et al.* Frequencies of HLA-A2 alleles in five U.S. population groups. *Hum Immunol* 2000;61:334–40.
- 57 Krause A, Guo H-F, Latouche J-B, *et al.* Antigen-Dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. *Journal of Experimental Medicine* 1998;188:619–26.
- 58 Abate-Daga D, Davila ML. Car models: next-generation CAR modifications for enhanced T-cell function. *Mol Ther Oncolytics* 2016;3:16014.
- 59 Imai C, Mihara K, Andreansky M, *et al.* Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. *Leukemia* 2004;18:676–84.
- 60 Maude SL, Laetsch TW, Buechner J, *et al.* Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med Overseas Ed* 2018;378:439–48.
- 61 Brown CE, Alizadeh D, Starr R, *et al.* Regression of glioblastoma after chimeric antigen receptor T-cell therapy. *N Engl J Med* 2016;375:2561–9.
- 62 Specht JM, Lee S, Turtle C, *et al.* Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells. *Journal of Clinical Oncology* 2018;36:TPS79.
- 63 Adusumilli PS, Zauderer MG, Rusch VW, *et al.* Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent. *Journal of Clinical Oncology* 2019;37:2511.
- 64 Ahmed N, Brawley V, Hegde M, *et al.* Her2-Specific chimeric antigen Receptor-Modified virus-specific T cells for progressive glioblastoma. *JAMA Oncology* 2017;3:1094–101.
- 65 Narayan V, Gladney W, Plesa G, *et al.* A phase I clinical trial of PSMA-directed/TGF $\beta$ -insensitive CAR-T cells in metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology* 2019;37:TPS347.
- 66 Dorff TB, Blanchard S, Carruth P, *et al.* A phase I study to evaluate PSCA-targeting chimeric antigen receptor (CAR)-T cells for patients with PSCA+ metastatic castration-resistant prostate cancer (mCRPC). *Journal of Clinical Oncology* 2020;38:TPS250.
- 67 Becerra CR, Manji GA, Kim DW, *et al.* Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results with cyclophosphamide (Cy)  $\pm$  fludarabine (Flu) lymphodepletion (LD). *Journal of Clinical Oncology* 2019;37:2536.
- 68 Zhan X, Wang B, Li Z, *et al.* Phase I trial of claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma. *Journal of Clinical Oncology* 2019;37:2509.
- 69 Brown CE, Mackall CL. Car T cell therapy: inroads to response and resistance. *Nat Rev Immunol* 2019;19:73–4.
- 70 Chen N, Li X, Chintala NK, *et al.* Driving cars on the uneven road of antigen heterogeneity in solid tumors. *Curr Opin Immunol* 2018;51:103–10.
- 71 Chmielewski M, Abken H. Trucks, the fourth-generation CAR T cells: current developments and clinical translation. *Advances In Cell And Gene Therapy* 2020;3:e84.
- 72 Chmielewski M, Kopecky C, Hombach AA, *et al.* IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. *Cancer Res* 2011;71:5697–706.
- 73 Patel AP, Tirosh I, Trombetta JJ, *et al.* Single-Cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* 2014;344:1396–401.
- 74 Ricketts CJ, Linehan WM, Marston Linehan W. Intratumoral heterogeneity in kidney cancer. *Nat Genet* 2014;46:214–5.
- 75 Zhang J, Fujimoto J, Zhang J, *et al.* Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. *Science* 2014;346:256–9.
- 76 O'Rourke DM, Nasrallah MP, Desai A, *et al.* A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Sci Transl Med* 2017;9:eaad0984.
- 77 Choe JH, Watchmaker PB, Simic MS. Multi-antigen recognition circuits overcome challenges of specificity, heterogeneity, and durability in T cell therapy for glioblastoma. *bioRxiv* 2021.
- 78 Morsut L, Roybal KT, Xiong X, *et al.* Engineering customized cell sensing and response behaviors using synthetic Notch receptors. *Cell* 2016;164:780–91.
- 79 Roybal KT, Williams JZ, Morsut L, *et al.* Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. *Cell* 2016;167:419–32.
- 80 Wilkie S, van Schalkwyk MCI, Hobbs S, *et al.* Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors

- engineered to provide complementary signaling. *J Clin Immunol* 2012;32:1059–70.
- 81 Thistlethwaite FC, Gilham DE, Guest RD, *et al.* The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. *Cancer Immunology, Immunotherapy* 2017;66:1425–36.
- 82 Lamers C, Sleijfer S, Vulto AG, *et al.* Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. *Journal of Oncol* 2006;24:e20–2.
- 83 Gajewski TF, Meng Y, Blank C, *et al.* Immune resistance orchestrated by the tumor microenvironment. *Immunol Rev* 2006;213:131–45.
- 84 Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. *Cancer Cell* 2017;31:311–25.
- 85 Harlin H, Meng Y, Peterson AC, *et al.* Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. *Cancer Res* 2009;69:3077–85.
- 86 Newick K, O'Brien S, Moon E, *et al.* Car T cell therapy for solid tumors. *Annu Rev Med* 2017;68:139–52.
- 87 Srivastava S, Riddell SR. Chimeric antigen receptor T cell therapy: challenges to Bench-to-Bedside efficacy. *J.i.* 2018;200:459–68.
- 88 Tredan O, Galmarini CM, Patel K, *et al.* Drug resistance and the solid tumor microenvironment. *JNCI Journal of the National Cancer Institute* 2007;99:1441–54.
- 89 Mirzaei HR, Rodriguez A, Shepphird J. Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications. *Front Immunol* 1850;2017:8.
- 90 Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol* 2015;15:486–99.
- 91 Miller BC, Sen DR, Al Abosy R, *et al.* Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. *Nat Immunol* 2019;20:326–36.
- 92 Wang D, Prager BC, Gimble RC, *et al.* Crispr screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies. *Cancer Discov* 2021;11:1192–211.
- 93 Ren J, Zhang X, Liu X, *et al.* A versatile system for rapid multiplex genome-edited CAR T cell generation. *Oncotarget* 2017;8:17002–11.
- 94 Kuhn NF, Purdon TJ, van Leeuwen DG, *et al.* Cd40 Ligand-Modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. *Cancer Cell* 2019;35:473–88.
- 95 Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. *Front Immunol* 2018;9:978.
- 96 Klichinsky M, Ruella M, Shestova O, *et al.* Human chimeric antigen receptor macrophages for cancer immunotherapy. *Nat Biotechnol* 2020;38:947–53.